

Gemini Bio-Products and StemBioSys Announce Strategic Partnership

** Gemini Bio-Products adds StemBioSys products to its portfolio*

West Sacramento, CA and San Antonio, TX, February 14, 2019 – Gemini Bio-Products (“Gemini”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), and StemBioSys are pleased to announce a strategic partnership that will bring StemBioSys’ entire selection of matrices and cells into the Gemini portfolio. Launching this week, customers will now have the ability to purchase StemBioSys’ proprietary and innovative CELLvo™ products directly from Gemini.

StemBioSys’ novel CELLvo™ matrices provide cells a home in which they can expand in a rapid yet natural way. Studies conducted by StemBioSys, its partners, and various customers have demonstrated that cells isolated and expanded on the CELLvo™ Matrix proliferate faster than on competitors’ products. The cells also retain their native phenotype better in comparison to the same cells grown using competitive products. StemBioSys also offers a variety of high quality cell products that are isolated and expanded on their CELLvo™ Matrix technology.

StemBioSys has plans to release nine additional CELLvo™ cell culture products over the course of 2019. Upon launch, Gemini will also offer these new products for purchase.

Dale Gordon, Gemini Bio-Products CEO, stated, “We’re thrilled to have the opportunity to partner with StemBioSys and believe their innovative tools and high-quality cells are the perfect complement our existing cell culture portfolio. Additionally, we plan to leverage each other’s unique competencies and networks to identify unmet market needs in order to accelerate product development for both organizations. We believe this partnership is a critical step for us as we strengthen our position in the Cell and Gene therapy space.”

Bob Hutchens, StemBioSys President and CEO, added, “We are very excited about our new partnership with Gemini Bio-Products. Our respective product lines, capabilities, and company cultures complement one another perfectly. We believe that there is a tremendous upside for both Gemini and StemBioSys in this partnership. The entire StemBioSys team and I look forward to working with Gemini Bio-Products in the years ahead.”

Rebecca Yu, Vice President of BelHealth and Gemini Board Member, added, “BelHealth is delighted to support both the Gemini and StemBioSys teams in this collaboration. Over the last few months, we have forged a strong relationship with Bob and StemBioSys’ Chairwoman of the Board, Cathy Burzik, who also recently joined Gemini’s board. We look forward to sponsoring the continued growth of both companies through product portfolio expansion and deeper channel penetration.”

About Gemini Bio-Products

Founded in 1985, Gemini is a supplier of cell culture media, sera, and other reagents to many of the world’s top research and academic communities, biotechnology firms, and pharmaceutical companies. Today, Gemini operates from a 14,000 square foot manufacturing facility in West Sacramento, California. A national sales force and an international distribution network serves cell culture laboratories worldwide.

About StemBioSys

StemBioSys, Inc., a privately held, San Antonio-based biomedical company, manufactures and develops innovative, advanced stem cell technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms – licensed from the University of Texas System – overcome key obstacles to creating clinically useful cell therapies. StemBioSys markets its products to the global research community under the CELLvo™ brand name.

About BelHealth Investment Partners

BelHealth Investment Partners, based in New York, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes would benefit from its extensive operating and private equity investment expertise. The firm invests across three core healthcare segments: Services, Products and Distribution. BelHealth is investing from its current \$350 million fund.

For further information, please visit:

BelHealth Investment Partners: www.belhealth.com

Contact:

BelHealth Investment Partners: Inder Tallur (347) 308-7018

Gemini Bio-Products: Dale Gordon (916) 273-5228